May 28, 2014Journal of Clinical OncologyOpen Access

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

View Full Paper

Ask AI

Bookmark

Authors

HBHarold J. BursteinBoston University STSarah TeminAmerican Society of Clinical Oncology HAHolly AndersonBabylon Breast Cancer Coalition

Discussion

Member takes

Implication

Clinical practice guideline update reports extended adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, highlighting benefits of ten-year treatment duration.

Key Points

Extended adjuvant endocrine therapy of 10 years total duration provides prolonged disease management in hormone receptor-positive breast cancer.
Clinical practice guideline update recommends 10 years total duration of tamoxifen or an aromatase inhibitor following an initial five-year course.
Highlights that premenopausal and postmenopausal women completing five years of tamoxifen should be offered extended endocrine therapy up to ten years.

Cite This Study

Burstein et al. (2014) studied this question.

synapsesocial.com/papers/69dcd25b0de68e8319e53a9b https://doi.org/10.1200/jco.2013.54.2258

View Full Paper

Ask AI

Bookmark

Implication

Clinical practice guideline update reports extended adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, highlighting benefits of ten-year treatment duration.

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Discussion

Member takes

Implication

Key Points

Cite This Study

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider